Please reference the list below for active Phase I/Translational clinical research being conducted by Comprehensive Cancer Centers. If a research offering is of interest, Email Us.
i2780 | A Phase 1/1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1454 alone and in Combination with Ipilimumab and Nivolumab **OPEN TO SQUAM ANAL CA (2L-4L) ONLY** |
i2896 | A Phase 1 Study of SGN-B6A in Advanced Solid Tumors **OPEN TO NSCLC, HNSCC, ESCC** |
i3068 | A Phase 1 First In Human Study Evaluating Safety, Pharmacokinetics And Efficacy Of ABBV-400 In Adult Subjects With Advanced Solid Tumors **COHORTS OPEN- NSCLC, GEA, c-MET amplified solid** |
i3169 | A Phase 1, Open-Label Study of ABSK121-NX to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumors |
i3162 | An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination with an Anti-PD1 Antibody in Patients with Advanced Solid Tumors |
i3189 | A Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Chiauranib for the Treatment of Advanced Solid Malignant Tumors and Relapsed/Refractory Small Cell Lung Cancer |
i3194 | A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors |
i3193 | An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations [SEACRAFT-1] |
i3209 | A Phase 1/2a Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors |